Skip to content

VYCOR MEDICAL, INC.: 10-Q filed 2025-11-14

What VYCOR MEDICAL, INC. reported in its quarterly report filed 2025-11-14 (fiscal Q3 2025): 43 published measures, 119 facts as tagged in accession 0001493152-25-022771.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-14
Fiscal period
fiscal Q3 2025
Accession
0001493152-25-022771 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All VYCOR MEDICAL, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-30941,195USD
At 2024-12-31998,117USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-304,965,388USD
At 2024-12-314,688,200USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-30-4,024,193USD
At 2025-06-30-3,866,944USD
At 2024-12-31-3,690,083USD
At 2024-09-30-3,683,346USD
At 2024-06-30-3,528,307USD
At 2023-12-31-3,325,476USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-3064,230USD
At 2024-12-31105,648USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-304,936USD92
2025-01-01 to 2025-09-30-9,740USD273
2024-07-01 to 2024-09-30-59,817USD92
2024-01-01 to 2024-09-30-100,463USD274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-52,703USD273
2024-01-01 to 2024-09-3098,391USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2025-01-01 to 2025-09-303,619USD273
2024-01-01 to 2024-09-305,368USD274

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-07-01 to 2025-09-30513,792USD92
2025-01-01 to 2025-09-301,446,523USD273
2024-07-01 to 2024-09-30390,852USD92
2024-01-01 to 2024-09-301,134,098USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-3014,062USD273
2024-01-01 to 2024-09-306,320USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-2,777USD273
2024-01-01 to 2024-09-30-4,369USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-33,586,170USD
At 2024-12-31-33,252,060USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-3033,372,796shares92
2025-01-01 to 2025-09-3033,372,796shares273
2024-07-01 to 2024-09-3032,903,493shares92
2024-01-01 to 2024-09-3032,721,056shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-3033,372,796shares92
2025-01-01 to 2025-09-3033,372,796shares273
2024-07-01 to 2024-09-3032,903,493shares92
2024-01-01 to 2024-09-3032,721,056shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-300USD/shares92
2025-01-01 to 2025-09-30-0.01USD/shares273
2024-07-01 to 2024-09-30-0.01USD/shares92
2024-01-01 to 2024-09-30-0.01USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-300USD/shares92
2025-01-01 to 2025-09-30-0.01USD/shares273
2024-07-01 to 2024-09-30-0.01USD/shares92
2024-01-01 to 2024-09-30-0.01USD/shares274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-09-30148,474USD
At 2024-12-31192,693USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-3048,838USD273
2024-01-01 to 2024-09-308,469USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-3032,085USD92
2025-01-01 to 2025-09-3070,425USD273
2024-07-01 to 2024-09-30-35,135USD92
2024-01-01 to 2024-09-30-28,489USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-30662,596USD
At 2024-12-31632,982USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-304,815,077USD
At 2024-12-314,496,543USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-3092,821USD
At 2024-12-31147,569USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-09-30326,052USD
At 2024-12-31245,260USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-30419,847USD92
2025-01-01 to 2025-09-301,155,312USD273
2024-07-01 to 2024-09-30389,191USD92
2024-01-01 to 2024-09-301,053,622USD274

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-09-30167,415USD
At 2024-12-31159,452USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30451,932USD92
2025-01-01 to 2025-09-301,225,737USD273
2024-07-01 to 2024-09-30354,056USD92
2024-01-01 to 2024-09-301,025,133USD274

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2025-07-01 to 2025-09-30404,967USD92
2025-01-01 to 2025-09-301,100,708USD273
2024-07-01 to 2024-09-30367,886USD92
2024-01-01 to 2024-09-301,000,293USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-01-01 to 2025-09-309,963USD273
2024-07-01 to 2024-09-306,425USD92
2024-01-01 to 2024-09-308,688USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-3033,372,796shares
At 2024-12-3133,372,796shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-3029,431,959USD
At 2024-12-3129,431,959USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2025-09-30127,677USD
At 2024-12-31127,677USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-09-3067,615USD
At 2024-12-31103,705USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-09-3064,745USD
At 2024-12-31100,379USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-09-30127,231USD
At 2024-12-31157,545USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-30103,474USD
At 2024-12-31121,705USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-304,990USD92
2025-01-01 to 2025-09-30-7,811USD273
2024-07-01 to 2024-09-30-59,770USD92
2024-01-01 to 2024-09-30-100,266USD274

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2025-07-01 to 2025-09-304,936USD92
2025-01-01 to 2025-09-30-9,740USD273
2024-07-01 to 2024-09-30-59,817USD92
2024-01-01 to 2024-09-30-100,463USD274

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-157,249USD92
2025-01-01 to 2025-09-30-334,110USD273
2024-07-01 to 2024-09-30-222,002USD92
2024-01-01 to 2024-09-30-424,833USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-01-01 to 2025-09-3046,999USD273
2024-01-01 to 2024-09-3047,041USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-27,095USD92
2025-01-01 to 2025-09-30-78,236USD273
2024-07-01 to 2024-09-30-24,635USD92
2024-01-01 to 2024-09-30-71,777USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-09-3019,883USD273
2024-01-01 to 2024-09-304,050USD274

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-3083,483USD273
2024-01-01 to 2024-09-3026,844USD274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-301,736USD273
2024-01-01 to 2024-09-30-46,518USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-54,748USD273
2024-01-01 to 2024-09-3033,179USD274

Inspect the source

Entity
VYCOR MEDICAL, INC. / CIK 0001424768
Captured
2026-09-20T08:03:40.055Z
SEC response SHA-256
5a14e6ff2e4ebac913c15e977f951bb2964df57677e781dac80300af4dfd59db

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001424768.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))